Skip to contentH
Halozyme Therapeutics, Inc.
H
HALOHalozyme Therapeutics, Inc. Q4 2014 · 10-K
Revenue$30.38M$30.38M+143.0% vs Q4 2013 Net Income-$5.27M-$5.27MN/M vs Q4 2013 EPS Diluted-$0.04-$0.04N/M vs Q4 2013 Gross Profit$3,997,000−36.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
derived
Operating Cash Flowderived-$939,000N/M Free Cash Flowderived-$1,175,000N/M Margins · derivedGross margin13.2%−37.0 pt vs Q4 2013
Operating margin-12.7%+157.9 pt vs Q4 2013
Net margin-17.4%+158.5 pt vs Q4 2013
ended Dec 31, 2014 · filed Mar 2, 2015 · 61 d after period end